Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics

Sanjay Kalra; Saptarshi Bhattacharya; Shehla Shaikh

PDF

Published: 2022-07-01

Keywords:

Gluconeogenesis, imeglimin, oxidative phosphorylation inhibitor, mitochondria, pharmacotherapeutics, type 2 diabetes mellitus

Sanjay Kalra

Dept. of Endocrinology, Bharti Hospital, Karnal, Haryana, India; University Center for Research & Development, Chandigarh University, Mohali, Punjab, India

Saptarshi Bhattacharya

Dept. of Endocrinology, Apollo Indraprastha Hospital, New Delhi, India

Shehla Shaikh

Dept. of Endocrinology, Saifee Hospital, Mumbai, Maharashtra, India

Abstract

Type 2 diabetes mellitus (T2DM) is a multifactorial disease. Newer facets of its causation, clinical course, complications and therapy are being unraveled regularly. This editorial describes imeglimin, a first-of-class oxidative phosphorylation inhibitor, that has been approved for T2DM in Japan and India.

Issue

Vol. 23 No. 3 (2022)

Section

Clinical Perspectives

This work is licensed under a Creative Commons Attribution 4.0 International License.

Make a Submission

Explore

About the Journal
Editorial Team

Submission guidelines

Conflicts of Interest
Publication Policy
Ethics
Language editing services

Articles and Issues

Contact the journal

Editorial Board Members

Founder: Late Dr. K.K Aggarwal, India
CMD and Group Editor-in-Chief: Dr. Veena Aggarwal, India
Editor-in-Chief: Dr Sanjay Kalra, India
Dr Zhanay Akanov, AAA Medical Clinic, Ministry of Health, Kazakhstan
Dr Sandeep Chaudhary, M.C Specialty Hospital, Dubai, UAE
Dr Khalid Shaikh, Royal Oman Police Hospital, Oman
Dr Ketut Suastika, Udayana University, Indonesia
Dr Guru Dhakal, Khesar Gyalpo University of Medical Sciences of Bhutan, Bhutan
Dr Jeyakantha Ratnasingam, University of Malaya, Malaysia
Dr Rakesh Sahay, Osmania Medical College, Hyderabad, Telangana, India
Dr Nitin Kapoor, Christian Medical College, India
Dr. Saptarshi Bhattacharya, Indraprastha Apollo Hospitals, Delhi, India
Dr Fatemeh Esfahanianm, Tehran University of Medical Sciences, Iran
Dr Jubbin Jacob, Christian Medical College Ludhiana, India
Dr Ali Latheef, Consultant Endocrinologist, Tree Top Hospital, Maldives
Dr Vivien Lim, Senior Consultant, Department of Endocrinology, Singapore eneral Hospital, Singapore
Dr Jeremy Robles, Consultant Endocrinologist, Chong Hua Hospital, Cebu, Philippines
Dr Md. Wali Naseri, Endocrinologist, Jamhuriat Hospital, Kabul, Afghanistan
Dr Syed Abbas Raza, Consultant & Head of Endocrinology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan
Dr Dina Shrestha, Consultant Endocrinologist, Norvic International Hospital & Medical College, Kathmandu, Nepal
Dr Tint Swe Latt, Consultant & Head of Endocrinology, National Diabetes Center & Bahosi Clinic, Yangon, Myanmar
Dr Ahmed El Nahary, Consultant, Diabetologist, 2nd Family Medicine Clinic, King Abdulaziz Medical City, Riyadh, Saudi Arabia
Dr Shahjada Selim, Associate Professor & Head, Clinical & Experimental Endocrinology, BSMMU, Dhaka, Bangladesh
Dr Noel Somasundaram, Consultant Endocrinologist, National Hospital of Sri Lanka, Colombo, Sri Lanka
Dr Hasan Aydin, Endocrinologist & Diabetes Specialist, Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey